Key result
Insertion of totally implantable venous access devices in the right internal jugular vein significantly reduced the risk of thrombotic occlusion compared to the left internal jugular vein (OR 0.528).
Why the study?
Thrombotic occlusion is the most common functional complication of totally implantable venous access devices (TIVADs) during the off-treatment period.
Population
1586 eligible patients with breast cancer with TIVADs
Comparison
Risk factors for TIVADs-related thrombotic occlusion
Design
Retrospective observational cohort study
Authors
Loading...
May support preferring right IJ insertion, smaller catheters, and shorter dwell times to lower TIVAD occlusion risk in breast cancer; leaves open prospective validation.
Observational (n=1,586)
No
Odds Ratio: 0.528 (95% CI 0.343–0.813)
Absolute Event Rate: 4.5% vs 7.9%
p-value: p=0.004
In breast cancer patients with TIVADs, insertion in the right internal jugular vein, smaller catheter size, and shorter indwelling time are associated with a lower incidence of thrombotic occlusion.
Liu et al. (2023) conducted an observational in Breast cancer with totally implantable venous access devices (TIVADs) (n=1,586). Right internal jugular vein insertion vs. Left internal jugular vein insertion was evaluated on TIVAD-related thrombotic occlusion (OR 0.528, 95% CI 0.343-0.813, p=0.004). Insertion of totally implantable venous access devices in the right internal jugular vein significantly reduced the risk of thrombotic occlusion compared to the left internal jugular vein (OR 0.528).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: